CIK 0001858848
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Tenaya Therapeutics, Inc.
Sign in to watch- Ticker
- TNYA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813789973
- Phone
- +1 415-865-2066
- Business address
- 171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-15 | Tingley Whittemore Chief Medical Officer | Grant or award | +35,000 | 35,000 | ||
| 2023-02-15 | Tingley Whittemore Chief Medical Officer | Grant or award | +45,000 | 80,000 | ||
| 2023-02-15 | Tingley Whittemore Chief Medical Officer | Grant or award · Stock Option (Right to buy) | +205,000 | 205,000 | ||
| 2023-02-15 | PATTERSON LEONE D Chief Fin. and Bus. Officer | Grant or award | +30,000 | 32,000 | ||
| 2023-02-15 | PATTERSON LEONE D Chief Fin. and Bus. Officer | Grant or award | +35,000 | 67,000 | ||
| 2023-02-15 | PATTERSON LEONE D Chief Fin. and Bus. Officer | Grant or award · Stock Option (Right to buy) | +190,000 | 190,000 | ||
| 2023-02-15 | Ali Faraz Chief Executive Officer | Grant or award | +125,000 | 125,000 | ||
| 2023-02-15 | Ali Faraz Chief Executive Officer | Grant or award · Stock Option (Right to buy) | +675,000 | 675,000 | ||
| 2023-02-08 | COLUMN GROUP III GP, LP 10% owner | Purchase | +1,500,000 | $2.60 | $3.9M | 11,370,274 |
| 2023-02-08 | GOEDDEL DAVID V Director | Purchase | +1,500,000 | $2.60 | $3.9M | 11,370,274 |
| 2023-01-19 | COLUMN GROUP III GP, LP 10% owner | Purchase | +69,739 | $2.50 | $174K | 9,870,274 |
| 2023-01-19 | GOEDDEL DAVID V Director | Purchase | +69,739 | $2.50 | $174K | 9,870,274 |
| 2023-01-18 | COLUMN GROUP III GP, LP 10% owner | Purchase | +135,688 | $2.52 | $341K | 9,800,535 |
| 2023-01-18 | GOEDDEL DAVID V Director | Purchase | +135,688 | $2.52 | $341K | 9,800,535 |
| 2023-01-17 | COLUMN GROUP III GP, LP 10% owner | Purchase | +49,463 | $2.49 | $123K | 9,664,847 |
| 2023-01-17 | GOEDDEL DAVID V Director | Purchase | +49,463 | $2.49 | $123K | 9,664,847 |
| 2022-12-05 | Burroughs Amy L. Director | Grant or award · Stock Option (Right to buy) | +40,000 | 40,000 | ||
| 2022-11-21 | Srivastava Deepak Director | Purchase | +230,769 | $2.60 | $600K | 372,435 |
| 2022-11-21 | COLUMN GROUP III GP, LP 10% owner | Purchase | +9,615,384 | $2.60 | $25.0M | 9,615,384 |
| 2022-11-21 | GOEDDEL DAVID V Director | Purchase | +9,615,384 | $2.60 | $25.0M | 9,615,384 |
Page 9 of 12 · 228 trades